Literature DB >> 24435452

Plasminogen activator inhibitor-1 -675 4G/5G polymorphism and polycystic ovary syndrome risk: a meta analysis.

Ying Liu1, Mei-Guo Sun, Rong Jiang, Rui Ding, Zhen Che, Yan-Yan Chen, Ci-Jiang Yao, Xiao-Xia Zhu, Ji-Yu Cao.   

Abstract

PURPOSE: Several studies have reported that excessive amounts of plasminogen activator inhibitor-1(PAI-1) might increase the incidence of polycystic ovary syndrome(PCOS), but so far the published results were inconsistent. The aim of this study was to further investigate the association between PAI-1 gene polymorphism and the susceptibility to PCOS by performing a meta-analysis.
METHODS: A comprehensive literature search for relevant studies was conducted on google scholar, PubMed, the Chinese National Knowledge Infrastructure (CNKI) and the Chinese Biomedical Literature Database (CBM). This meta-analysis was performed using the STATA 11.0 software and the pooled odds ratio (OR) with 95% confidence interval (CI) was calculated.
RESULTS: Ten case-control studies were included in this meta-analysis with a total of 2,079 cases and 1,556 controls. The results showed that PAI-1 -675 4G/5G polymorphism may increase the risk of PCOS, especially among Asian populations. However, there was no statistically significant association between the polymorphism and PCOS risk in Caucasians.
CONCLUSION: Our meta-analysis suggests that PAI-1 -675 4G/5G polymorphism may contribute to increasing susceptibility to PCOS in Asians. Detection of the PAI-1 gene polymorphism might be a promising biomarker for the susceptibility of PCOS.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24435452      PMCID: PMC3947070          DOI: 10.1007/s10815-013-0171-2

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  35 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

Review 2.  Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology.

Authors:  John Attia; Ammarin Thakkinstian; Catherine D'Este
Journal:  J Clin Epidemiol       Date:  2003-04       Impact factor: 6.437

3.  Thrombogenesis in atrial fibrillation: contributing mechanisms and natural history.

Authors:  Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2008-10-19       Impact factor: 2.300

Review 4.  Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth.

Authors:  Evanthia Diamanti-Kandarakis; Christina Piperi
Journal:  Hum Reprod Update       Date:  2005-07-01       Impact factor: 15.610

5.  Coagulation and fibrinolytic indices during the first trimester of pregnancy in women with polycystic ovary syndrome: a preliminary study.

Authors:  Yu Shan; Aiming Wang; Ying Sun; Wen Jiang; Baosen Pang; Zhiyuan An; Xin Du; Wei Wang; Zhongwei Huang
Journal:  Reprod Sci       Date:  2013-04-12       Impact factor: 3.060

6.  Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome.

Authors:  Charles J Glueck; Luann Sieve; Binghua Zhu; Ping Wang
Journal:  Metabolism       Date:  2006-03       Impact factor: 8.694

7.  The plasminogen activator inhibitor-1 (PAI-1) gene -844 A/G and -675 4G/5G promoter polymorphism significantly influences plasma PAI-1 levels in women with polycystic ovary syndrome.

Authors:  Sun Lin; Zhang Huiya; Liu Bo; Wei Wei; Guan Yongmei
Journal:  Endocrine       Date:  2009-10-24       Impact factor: 3.633

8.  Correlation between plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G polymorphism and metabolic/proinflammatory factors in polycystic ovary syndrome.

Authors:  M F Sales; M O Sóter; A L Candido; A P Fernandes; F R Oliveira; A C S Ferreira; M O Sousa; C N Ferreira; K B Gomes
Journal:  Gynecol Endocrinol       Date:  2013-07-30       Impact factor: 2.260

9.  Prevalence of polycystic ovary syndrome in women in China: a large community-based study.

Authors:  Rong Li; Qiufang Zhang; Dongzi Yang; Shangwei Li; Shulan Lu; Xiaoke Wu; Zhaolian Wei; Xueru Song; Xiuxia Wang; Shuxin Fu; Jinfang Lin; Yimin Zhu; Yong Jiang; Huai L Feng; Jie Qiao
Journal:  Hum Reprod       Date:  2013-06-27       Impact factor: 6.918

Review 10.  Association of plasminogen activator inhibitor-type 1 (-675 4G/5G) polymorphism with pre-eclampsia: systematic review.

Authors:  Jessie A Morgan; Sarah Bombell; William McGuire
Journal:  PLoS One       Date:  2013-02-15       Impact factor: 3.240

View more
  1 in total

1.  Preliminary Results for Personalized Therapy in Pregnant Women with Polycystic Ovary Syndrome During the COVID-19 Pandemic.

Authors:  Małgorzata Jerzak; Monika Szafarowska
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2022-03-24       Impact factor: 3.831

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.